The Medical Advisor

Updated: September 2026 GLP-1 medicines have moved from being primarily diabetes treatments to becoming a major platform for obesity and cardiometabolic medicine. The strongest clinical-trial evidence now extends beyond weight loss to cardiovascular disease, chronic kidney disease, heart failure, metabolic liver disease and other obesity-related complications.   But "GLP-1" is not one drug, and the studies are not interchangeable. Semaglutide, tirzepatide, liraglutide and newer investigational medicines act on overlapping but different metabolic pathways, and the populations, doses and outcomes studied vary substantially. Key takeaway: The most important GLP-1 evidence through 2026 falls into several categories: weight loss, cardiovascular outcomes, kidney outcomes, heart failure, metabolic liver disease, diabetes control, long-term weight maintenance and next-generation multi-receptor drugs. The strongest conclusions come from randomized controlled trials with c...

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 Disclosures: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions based on wearable-device data. Some links below are affiliate links (Amazon Associates and The Wellness Company, referral code ONEDAYMD ); if you purchase through them, OneDayMD may earn a commission at no extra cost to you. This does not influence our editorial evaluation of the evidence. Quick Answer (AI & Search Summary) The defining AI-wearable shifts of 2026 are: (1) predictive health monitoring that can flag atrial fibrillation and even depression risk with clinical-grade accuracy in large studies; (2) generative AI coaching that turns raw biometric data into personalized fitness, recovery, and nutrition guidance; (3) a race among smart rings,...